Navigation Links
Kiadis Pharma Announces ATIR Interim Clinical Results
Date:10/10/2007

Successful Independent Clinical Evaluation of ATIR by Dr. Velardi for

Mismatched Bone Marrow Transplantation

AMSTERDAM, Netherlands, Oct. 10 /PRNewswire/ -- Kiadis Pharma today announced interim results of a physician initiated European Phase II clinical study for its lead product ATIR. Professor Velardi from the University of Perugia in Italy presented the successful treatment of thirteen end stage blood cancer patients with a mismatched bone marrow transplantation during the 5th workshop on "Haploidentical Stem cell Transplantation" in Catania, Italy. The results are an important milestone in the development of ATIR as a revolutionary approach to provide a safe and potentially life-saving mismatched bone marrow transplantation as treatment option for end-stage blood cancer patients.

Bone marrow transplantations are currently limited because of the high risk of Graft versus Host Disease (GvHD). This is a severe and potentially life-threatening complication in which the donor immune cells recognize and attack the patient's tissues and organs. Therefore it is currently essential that the patient and donor blood systems (the human leukocyte antigens, HLA) are highly similar in order to reduce the chance of acute GvHD. As a consequence, bone marrow transplantations strongly rely on the availability of a matching donor. However, the timely availability of a matching donor is a limiting factor for many patients to receive a bone marrow transplantation. Kiadis Pharma's ATIR is under development to prevent acute GvHD by elimination of the immune cells causing acute GvHD. A successful development would enable the performance of mismatched donor transplantations, including donor immune cells that can fight infections and the cancer without causing GvHD complications. Because ATIR eliminates acute GvHD causing cells, the transplantation can be performed without the currently standard immune suppressant regime post transplantation. This subsequently allows the donor immune system to rapidly develop helping the patient to fight infections, another major life threatening complication of bone marrow transplantations.

Professor Velardi, a key opinion leader in the field of mismatched allogeneic transplantations, has presented the clinical results of thirteen end stage blood cancer patients who received bone marrow transplants from mismatched donors, including donor immune cells that are selectively depleted of acute GvHD causing cells using ATIR. No immune suppressants were used post transplantation as a standard regime. No patient has developed lethal acute Graft versus Host Disease, the major complication that prohibits the use of this treatment without ATIR. The patients rapidly developed a new donor immune system as assessed by the rapid expansion of immune cells in the patients. Detailed analysis revealed the presence of pathogen specific donor immune cells in the patients. In particular immune cells recognizing pathogenic fungi, like Aspergillus and viruses like Cytomegalovirus (CMV) could be detected post transplantation.

These specific pathogens are the major cause of death by infections after bone marrow transplantation. This shows that the ATIR treated immune cells are functional and could fight infections without causing lethal acute GvHD in these patients.

"Bone marrow transplantations are often the only treatment option left for end-stage blood cancer patients. But too many patients simply do not find a suitable matched donor in time," said Dr. Andrea Velardi, M.D., Professor of Clinical Immunology at the University of Perugia. "The interim results of our study show a rapid immune reconstitution in transplanted patients provided with ATIR treated immune cells from mismatched donors. Without ATIR treatment this would not be possible because of the high risk of acute Graft versus Host Disease (GvHD) with mismatched donor immune cells. This is obviously a very hopeful development for a large patient group."

The physician initiated European ATIR Phase II trial by Prof. Andrea Velardi, M.D. is the second clinical trial of ATIR for mismatched bone marrow transplantations. Kiadis Pharma conducts a company-sponsored trial ongoing in North America. Both trials aim to investigate the potential of ATIR to make the use of a mismatched bone marrow transplantation a feasible treatment for blood cancer patients who are not responding to other treatments and who do not have access to a matched donor in time. For these patients ATIR can enable a potentially life-saving transplantation.

"The broad endorsement of ATIR by key opinion leaders in this field is exemplified by the initiative of Professor Velardi," commented Dr. Manja Bouman, CEO Kiadis Pharma. "These excellent results in the Perugia trial provide Kiadis Pharma with important external validation."

About ATIR

ATIR is being developed to enable the use of a mismatched donor for an allogeneic bone marrow transplantation for end stage blood cancer patients. ATIR selectively eliminates from a mismatched graft the immune cells that cause acute Graft versus Host Disease, a severe and potentially lethal complication with allogeneic bone marrow transplantations.

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with four products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address high-unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures performed in blood cancer patients. Kiadis Pharma is headquartered in Amsterdam, the Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit http://www.kiadis.com.


'/>"/>
SOURCE Kiadis Pharma B.V.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. India to benefit from pharma companies move
2. South Africa Wins landmark case against pharmaceutical giants
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
5. Pharma cos must forge Strategic alliances
6. Jharkhand Pharmacies Refuse To Sell Viagra
7. Setting up a new pharmaceutical industry in India
8. Medicis Pharmaceutical company enters pediatric market
9. Supply of Radiopharmaceuticals Hampered by Attacks
10. Pharma majors gear to supply anti-anthrax drug
11. Pharmacies in for a dose of bitter medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... , ... Nike Rugby Camp's success is due in large part to Ethan ... Rugby Camps and current Nike Camp director, has offered an all abilities rugby camp ... excited for our eighth summer here in San Diego,” says Willis. "We take great ...
(Date:5/4/2016)... ... , ... Hight-Doland Insurance Agency’s new community involvement program which serves families of ... of Southwest Louisiana to help provide positive mentoring for local youth. Donations to this ... of Southwest Louisiana has been helping to guide the area’s youth for over 30 ...
(Date:5/4/2016)... ... ... May kicked off with Melanoma Monday , a multi-agency effort to raise ... encouraging her patients, as well as residents all around Dallas, Cleburne, Irving, and Plano, ... in the future. , The dermatology-specific awareness month ends with “Don’t Fry Day,” established ...
(Date:5/4/2016)... Diego, California (PRWEB) , ... May 04, 2016 ... ... wearable technology that is transforming breastfeeding for nursing mothers. The company’s patented technology, ... intake while breastfeeding. Today, the company announced that the technology is now available ...
(Date:5/4/2016)... ... May 04, 2016 , ... Francesca Loparco, Co-Founder of Queen City Dream Cars, ... same-day LASIK procedure at Christenbury Eye Center. The entrepreneur struggled with her ... surgery the same day as her in-office consultation and eye exam. Francesca’s eyesight was ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... May 3, 2016 BioNovus Innovations LLC ... for Advancing Medical Innovation (IAMI) today announced a ... diagnostics and medical devices. An agreement ... rights to license, develop and commercialize medical innovations ... "This partnership represents a significant advance in ...
(Date:5/3/2016)... ACME Markets, Delaware ... Delaware County Councilman Dave White announced ... ACME pharmacies across Delaware County ... Prevention (CDC), naloxone has saved 26,463 lives nationwide over the past ... Delaware County were authorized to administer naloxone to overdose ...
(Date:5/3/2016)... FLINT, Mich. , May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today ... The company released a video of two patients who tell their personal story and encourage ... hepatitis.   Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
Breaking Medicine Technology: